Table 3 Outcomes assessment.

From: Multicenter randomized trial assessing efficacy and safety of aerosolized dornase Alfa in COVID-19 ARDS

Median (Q1, Q3) or n/N (%)

CONTROL (N = 38)

EXPERIMENTAL (N = 39)

Adjusted** OR [95CI] or IRR [95CI] or β [95CI]

Improvement of at least one grade in ARDS scale between D0 and D7 (imputed)

11/38 (29%)

7/39 (18%)

0.33 [0.09–1.14]

All causes mortality at D28

10/38 (26%)

14/39 (36%)

2.66 [0.88–8.03]

Number of days alive without invasive mechanical ventilation between D0 and D28

2 (0, 17)

1 (0, 14)

0.71 [0.39–1.28]

Number of days alive out of resuscitation unit between D0 and D28

0 (0, 8)

0 (0, 10)

0.69 [0.32–1.48]

Variation of PaO2/FiO2 mean ratio between D0 et D7*

–13 (–54, 38)

–3 (–36, 22)

10.8 [-19.24–40.85]

Variation of FiO2 between D0 et D7*

0 (–9, 10)

–5 (–10, 10)

–1.91 [–12.61–8.78]

Variation of PEEP between D0 et D7*

1 (–1, 5)

1 (0, 3)

–1.11 [–3.32–1.10]

  1. * 4 missing data for Variation of PaO2/FiO2 mean ratio between D0 et D7 in control group and 3 in experimental. 4 missing data for Variation of FiO2 between D0 et D7 in each group. 5 missing data for Variation of PEEP between D0 et D7 in control group and 6 in experimental. Q1: first quartile, Q3: third quartile, OR: odds ratio, IRR: Incidence Rate Ratio.
  2. ** All models are adjusted for PaO2/FiO2 mean ratio at inclusion (except Variation of PaO2/FiO2 mean ratio between D0 et D7), prone position, administration of anti-inflammatory drugs and administration of anti-infectious drugs during the first 7 days.
Back to article page